Presenting the Journey to the Clinic for a Novel Bispecific Antibody EpiTAC that Selectively Degrades EGFR in Tumours

• EPI-326 is a bispecific EGFR EpiTAC that drives targeted degradation of mutant and wild type EGFR specifically within tumours
• Highlighting deep and durable efficacy, favourable safety and PK, and path to IND and clinic for EPI-326
• Demonstrating preclinical advancements with in vivo data on additional programs, emphasising catalytic degrader mechanisms and tissue-specific delivery
• Exploring the transformative potential of bispecific antibody degraders for oncology and inflammatory diseases

Speakers:

Shyra gardai

CSO

EpiBiologics